| Mark C Garabedian, | |
|
6372 Mechanicsville Tpke, Suite 103, Mechanicsville, VA 23111-4705 | |
| (804) 730-4690 | |
| (804) 559-0333 |
| Full Name | Mark C Garabedian |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 6372 Mechanicsville Tpke, Mechanicsville, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285792978 | NPI | - | NPPES |
| 01443329 | Medicaid | NY | |
| C06115 | Other | VA | GROUP PTAN |
| C06193 | Other | VA | GROUP PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 1892751 (New York) | Secondary |
| 208000000X | Pediatrics | 0101245096 (Virginia) | Primary |
| Entity Name | Bon Secours Memorial Regional Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881795557 PECOS PAC ID: 6507775293 Enrollment ID: O20040726000687 |
News Archive
The U.S. Food and Drug Administration today approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia (fever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells), in patients with non-myeloid (non-bone marrow) cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.
LabStyle Innovations Corp., developer of Dario, a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced today that it has filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration for the Dario Blood Glucose Monitoring System.
Researchers have developed a high-performance, low magnetic-field MRI system that produces superior images of the body's internal structures and is also safer.
Interleukin Genetics, Inc. today announced that on November 1, 2010 notification was received that it has been awarded two grants totaling $473,393 by the United States Government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the Company's genetic research projects related to obesity and osteoarthritis.
Rice University scientists are developing strategies to keep germs from evolving resistance to antibiotics by heading them off at the pass.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark C Garabedian, 6372 Mechanicsville Tpke, Suite 103, Mechanicsville, VA 23111-4705 Ph: (804) 730-4690 | Mark C Garabedian, 6372 Mechanicsville Tpke, Suite 103, Mechanicsville, VA 23111-4705 Ph: (804) 730-4690 |
News Archive
The U.S. Food and Drug Administration today approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia (fever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells), in patients with non-myeloid (non-bone marrow) cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.
LabStyle Innovations Corp., developer of Dario, a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced today that it has filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration for the Dario Blood Glucose Monitoring System.
Researchers have developed a high-performance, low magnetic-field MRI system that produces superior images of the body's internal structures and is also safer.
Interleukin Genetics, Inc. today announced that on November 1, 2010 notification was received that it has been awarded two grants totaling $473,393 by the United States Government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the Company's genetic research projects related to obesity and osteoarthritis.
Rice University scientists are developing strategies to keep germs from evolving resistance to antibiotics by heading them off at the pass.
› Verified 7 days ago
Aruna D. Dhru, M. D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9464 Chamberlayne Rd, Suite 101, Mechanicsville, VA 23116 Phone: 804-730-8040 Fax: 804-730-4161 | |
Christine M. Privitera, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6372 Mechanicsville Tpke, Suite 203, Mechanicsville, VA 23111 Phone: 804-730-4690 Fax: 804-559-0333 | |
Dr. Kimberly M. Phillips, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 7347 Bell Creek Rd, Suite 100, Mechanicsville, VA 23111 Phone: 804-559-9430 Fax: 804-559-2037 | |
Emmanuel E. Eugenio, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 6372 Mechanicsville Tpke, Suite 103, Mechanicsville, VA 23111 Phone: 804-730-4690 Fax: 804-559-0333 | |
Louise Carolyn Washington-alston, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6372 Mechanicsville Tpke, Suite 103, Mechanicsville, VA 23111 Phone: 804-730-4690 Fax: 804-559-0333 | |
Jerome M. Shalf, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6372 Mechanicsville Tpke, Suite 103, Mechanicsville, VA 23111 Phone: 804-730-4690 Fax: 804-559-0333 |